Mucosal immunization with DNA vaccines.
DNA vaccines represent a new approach to the control of infectious disease. Both cellular and humoral immune responses are induced without the attendant concerns associated with live, attenuated vaccines. The vast majority of DNA vaccines are delivered by parental routes, which rarely elicit immune responses at the mucosal epithelia, the primary sites of pathogen transmission. In view of the importance of mucosal and regional lymph node immunity in the control of pathogens transmitted across the mucosal epithelia, a number of groups, including our own, have developed immunization strategies that target plasmid DNA to mucosal inductive sites associated with the lymphoid tissues of the respiratory, gastrointestinal, and genital tracts. Here, we describe the procedures for the formulation and delivery of plasmid DNA to mucosal inductive tissues and address the theoretical basis to selection of particular mucosal locations for the induction of effective immune responses.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000235:genetics; D000818:Animals; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage; D005835:Genitalia / Q000276:immunology; D018928:Immunity, Mucosal / Q000276:immunology*; D007167:Immunotherapy; D008221:Lymphoid Tissue / Q000276:immunology / Q000473:pathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000276:immunology; D008297:Male; D009297:Nasal Mucosa / Q000276:immunology; D010957:Plasmids / Q000008:administration & dosage; D014611:Vaccination / Q000379:methods*; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000235:genetics
D000276:Adjuvants, Immunologic; D019444:Vaccines, DNA